SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs (India) concludes sale of business to Akorn, Inc

29 Feb 2012 Evaluate

Kilitch Drugs (India) has concluded the transaction of sale of company's business along with the Mumbai Business in accordance with the terms of the business transfer agreement and the Mumbai product transfer agreement. Pursuant to this the company has received an aggregate consideration of Rs 221.60 crore.

The company shall continue to carry on and expand the business of sales, marketing and distribution of eye care products, manufacturing from its Navi Mumbai facility and export of generic formulation products to certain overseas markets. The company has entered into certain agreements with Akorn for manufacture of products on contract manufacturing basis for Akorn.

Further, the company has also executed a management services and transition support agreement with Akorn where-under the company will provide certain transition and management services to Akorn for an additional consideration of Rs 32.50 lakh to facilitate transition of the business from the company to Akorn.

Last year in October, Kilitch Drugs (India) had entered into business transfer agreement (BTA) with Akron Inc., through its wholly owned Indian subsidiary, Akorn India for sale of its business which included research, development, manufacturing, marketing, importing and exporting of generics pharmaceuticals formulation products out of two factory units of the company situated at Himachal Pradesh to Akorn.

Kilitch Drugs (India) is engaged in the manufacture of injectibles such as gentamycin sulphate, dexamethason sodium phosphate, B-complex and others. Nasdaq-listed Akorn Inc is a niche generic pharmaceutical company.

Kilitch Drugs(India) Share Price

135.10 4.55 (3.49%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×